Inhibitor Therapeutics, Inc. (INTI)
Stock Price: $0.0401 USD
-0.0080 (-16.46%)
Updated Jan 19, 2021 3:05 PM EST - Market closed
| Market Cap | 16.44M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.84M |
| Shares Out | 373.15M |
| EPS (ttm) | -0.01 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Dividend Yield | n/a |
| Trading Day | January 19 |
| Last Price | $0.0401 |
| Previous Close | $0.0480 |
| Change ($) | -0.0080 |
| Change (%) | -16.46% |
| Day's Open | 0.0401 |
| Day's Range | 0.0401 - 0.0401 |
| Day's Volume | 2,000 |
| 52-Week Range | 0.03 - 0.138 |
News
There are no news available yet.
About INTI
Inhibitor Therapeutics operates as a pharmaceutical development company that discovers, develops, and plans to commercialize therapeutics to inhibit the progression of cancerous and non-cancerous proliferation disorders in the United States. The company's Hedgehog signaling pathway is a primary regulator of cellular processes in vertebrates, including cell differentiation, tissue polarity, and cell proliferation. It focuses on developing its lead product, SUBA-Itraconazole, a patented oral formulation for prostate and lung cancer. The company w... [Read more...]
| Industry Biotechnology | Founded 1992 |
| CEO Nicholas Virca | Employees 2 |
| Stock Exchange OTCMKTS | Ticker Symbol INTI |